Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Open-Label Arm of Ph 2 KeyVibe-002 Trial of MK-7684A (Coformulation of Vibostolimab and Keytruda) to continue in Previously Treated mNSCLC Patients

March 31, 2023

Ph 1b/2 Study initiated to Evaluate Pepinemab + Avelumab in 2L Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients

March 31, 2023

Ph 1/2 clinical trials of GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients discontinued

March 31, 2023

First Patient dosed in FRIDA, a Ph Ib trial with iadademstat in R/R FLT3-mutant AML patients

March 31, 2023

Clinical Hold Announced on XMT-2056 Ph 1 Clinical Trial

March 31, 2023

Ph 2/3 Trial for Eftilagimod Alpha plus Paclitaxel initiated in Metastatic Breast Cancer

March 31, 2023

First Lung Cancer Patient Dosed in Ph 1 Trial for BBP-398 in Combination with OPDIVO® (nivolumab)

March 31, 2023

First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

March 31, 2023

First Patient Dosed in Phase 2b Trial of IGV-001 for Glioblastoma

March 31, 2023

New Study Arm to Evaluate (Z)-Endoxifen added to the Ongoing I-SPY 2 Clinical Trial

March 31, 2023

First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

March 15, 2023

Clinical Hold on XMT-2056 Ph 1 Clinical Trial Announced

March 15, 2023

First Patient Dosed in Ph 1b/2a Trial Evaluating Bemcentinib in 1L NSCLC with STK11 Mutations

March 15, 2023

Enrollment initiated in Ph 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer

March 15, 2023

Clinical Study of JWATM214 initiated in Patients with Advanced HCC

March 15, 2023

Ph 3 KEYNOTE-671 Trial Met Primary Endpoint of EFS in Patients With Resectable Stage II, IIIA or IIIB NSCLC

March 15, 2023

Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Mets from NSCLC

March 15, 2023

First Patient dosed in Ph 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer

February 28, 2023

Trilaciclib Ph 3 PRESERVE 1 trial in CRC patients to discontinue after absence of efficacy signals in early data

February 22, 2023

Ph 3 Study of Uproleselan in R/R AML to continue to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee

February 22, 2023

Positive Initial Results From The MVP-S Ph 2B VITALIZE Trial Presented

February 22, 2023

Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

February 22, 2023

First Patient Dosed in ASPEN-07 Ph 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer

February 22, 2023

First Patients Dosed in Ph 2 Registrational Trial of Ziftomenib in NPM1-Mutant AML

February 22, 2023

Ph 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer initiated

February 22, 2023
Page1 … Page17 Page18 Page19 Page20 Page21 Page22

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.